Prenetics Global Limited (NASDAQ: PRE) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
18.57
+0.05+0.27%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -4.58 | Insider Own | 6.11% | Shs Outstand | 17.00M | Perf Week | -2.17% |
| Market Cap | 314.85M | Forward P/E | - | EPS next Y | -1.84 | Insider Trans | 0.00% | Shs Float | 12.63M | Perf Month | 9.39% |
| Enterprise Value | 292.85M | PEG | - | EPS next Q | -0.48 | Inst Own | 12.41% | Short Float | 5.27% | Perf Quarter | 8.81% |
| Income | -70.00M | P/S | 2.74 | EPS this Y | 16.81% | Inst Trans | - | Short Ratio | 2.90 | Perf Half Y | -3.04% |
| Sales | 115.00M | P/B | 1.96 | EPS next Y | 51.71% | ROA | -40.52% | Short Interest | 665.82K | Perf YTD | 17.59% |
| Book/sh | 9.47 | P/C | 13.12 | EPS next 5Y | - | ROE | -46.74% | 52W High | 23.70 -21.63% | Perf Year | 129.49% |
| Cash/sh | 1.41 | P/FCF | - | EPS past 3/5Y | - | ROIC | -25.54% | 52W Low | 7.20 157.94% | Perf 3Y | 56.29% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 91.99% 7.20% | Gross Margin | 58.32% | Volatility | 6.86% 10.62% | Perf 5Y | -83.53% |
| Dividend TTM | - | EV/Sales | 2.55 | EPS Y/Y TTM | -25.82% | Oper. Margin | -33.69% | ATR (14) | 1.88 | Perf 10Y | - |
| Dividend Ex-Date | Feb 17, 2016 | Quick Ratio | 4.60 | Sales Y/Y TTM | 270.97% | Profit Margin | -62.45% | RSI (14) | 47.46 | Recom | 2.00 |
| Dividend Gr. 3/5Y | -35.09% -21.51% | Current Ratio | 5.15 | EPS Q/Q | -70.00% | SMA20 | -2.60% | Beta | 0.22 | Target Price | 35.50 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | 111.76% | SMA50 | -3.99% | Rel Volume | 0.34 | Prev Close | 18.52 |
| Employees | 98 | LT Debt/Eq | 0.02 | Earnings | Aug 18 | SMA200 | 5.74% | Avg Volume | 236.42K | Price | 18.57 |
| IPO Date | Jul 16, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -33.77% -0.13% | Net Debt/EBITDA | 1.08 | Volume | 79,347 | Change | 0.27% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-15-26 | Reiterated | Lake Street | $29 → $35 | |
| Feb-11-26 | Initiated | Roth Capital | Buy | $36 |
Latest News
Aug-04-26
Jul-23-26
06:22AM
Jul-15-26
Jul-14-26
Jul-14-2602:01PM
01:35PM
Jul-09-26
Jul-09-2607:00AM
Jun-30-26
Jun-30-2609:30AM
Jun-16-26
Jun-16-2609:11AM
Company
As an investment holding company, Prenetics Global Limited specializes in providing diagnostic and genetic testing services. Its comprehensive product line features CircleDNA, a consumer-oriented genetic analysis solution, and the Circle HealthPod, an advanced health monitoring device. The Circle HealthPod facilitates rapid COVID-19 detection through nucleic acid amplification technology, suitable for both professional point-of-care and personal at-home use. Additionally, the company offers ColoClear, a non-invasive FIT-DNA screening test for colorectal cancer, and Circle SnapShot, a readily available at-home blood testing kit. Other diagnostic solutions in their portfolio include Circle Medical, Circle One, and F1x/Fem. Prenetics Global Limited was founded in 2014 and maintains its headquarters in Quarry Bay, Hong Kong.
Ownership
Total institutional ownership12.41%
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 115 | 92 | 31 | 22 | 13 | 13 | 65 | 9 | |
| Cost of Goods Sold Incl. D&A | 48 | 44 | 15 | 13 | 10 | 9 | 39 | 7 | |
| Gross Profit | 66 | 49 | 15 | 9 | 4 | 4 | 26 | 3 | |
| Selling, General and Administrative Excl. Other | 96 | 80 | 55 | 50 | 64 | 54 | 23 | 18 | |
| Research and Development | 4 | 5 | 11 | 12 | 6 | 6 | 3 | 3 | |
| Other Operating Expense | 4 | 2 | -2 | -1 | 0 | 0 | 1 | 3 | |
| Operating Income | -38 | -38 | -48 | -52 | -66 | -57 | -1 | -21 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -36 | 2 | -9 | -5 | -160 | -160 | -3 | 0 | |
| Net Income Before Taxes | -73 | -36 | -58 | -57 | -226 | -217 | -4 | -21 | |
| Income Taxes | 0 | 0 | -8 | 0 | 0 | 3 | -2 | -1 | |
| Consolidated Net Income | -70 | -38 | -46 | -63 | -190 | -174 | -2 | -20 | |
| Net Income From Continuing Operations | -73 | -36 | -50 | -56 | -226 | -219 | -2 | -20 | |
| Net Income | -70 | -38 | -46 | -63 | -190 | -174 | -2 | -20 | |
| EPS (Recurring) | -4.58 | -2.68 | -3.64 | -5.58 | -37.57 | -47.04 | -0.26 | -2.73 | |
| EPS (Basic, Before Extraordinaries) | -4.58 | -2.68 | -3.64 | -5.58 | -37.57 | -47.04 | -0.26 | -2.73 | |
| EPS (Diluted) | -4.58 | -2.68 | -3.64 | -5.58 | -37.57 | -47.04 | -0.26 | -2.73 | |
| EBITDA | -53 | -32 | -52 | -48 | -218 | -209 | -1 | -19 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.75 | 2.40 | 2.43 | 2.96 | 11.54 | 35.46 | — | — | |
| Gross Margin | 57.39 | 53.26 | 48.39 | 40.91 | 30.77 | 30.77 | 40.00 | 33.33 | |
| Operating Margin | -33.04 | -41.30 | -154.84 | -236.36 | -507.69 | -438.46 | -1.54 | -233.33 | |
| Net Margin | -60.87 | -41.30 | -148.39 | -286.36 | -1,461.54 | -1,338.46 | -3.08 | -222.22 | |
| Shares Outstanding | 17 | 14 | 13 | 11 | 5 | 4 | 7 | 7 | |
| Market Capitalization | 316 | 221 | 75 | 65 | 150 | 461 | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Leogrande Hudson Blake | Director | Jul 04 '26 | Option Exercise | 0.00 | 2,000 | 0 | 2,000 | Jul 07 |
| Cheng Yin Pan | Director | Jun 15 '26 | Option Exercise | 0.00 | 15,873 | 0 | 59,051 | Jun 16 |
| VANDERVEEN DAVID | Director | Jun 15 '26 | Option Exercise | 0.00 | 15,625 | 0 | 45,249 | Jun 16 |
| Desmet Laurie | EVP & COO, PartnerRe Ltd | Dec 21 '15 | Sale | 139.11 | 710 | 98,770 | 38,386 | Dec 22 |
| SAUTTER REMY | Director | Sep 17 '15 | Option Exercise | 71.12 | 5,282 | 375,656 | 24,866 | Sep 18 |
| SAUTTER REMY | Director | Sep 17 '15 | Sale | 138.46 | 5,282 | 731,339 | 19,584 | Sep 18 |
| SAUTTER REMY | Director | Sep 16 '15 | Sale | 138.46 | 15,613 | 2,161,844 | 19,584 | Sep 18 |
| SAUTTER REMY | Director | Sep 16 '15 | Option Exercise | 69.38 | 15,613 | 1,083,153 | 30,352 | Sep 18 |
| ZWIENER DAVID K | President & CEO PartnerRe Ltd. | Jun 15 '15 | Option Exercise | 130.50 | 978 | 127,629 | 24,003 | Jun 17 |
| SAUTTER REMY | Director | Jun 15 '15 | Option Exercise | 78.33 | 978 | 76,604 | 17,668 | Jun 17 |
| MONTUPET JEAN PAUL L | Director | Jun 15 '15 | Option Exercise | 78.28 | 1,137 | 89,001 | 17,054 | Jun 17 |
| MENDOZA ROBERTO G | Director | Jun 15 '15 | Option Exercise | 130.50 | 1,297 | 169,259 | 8,808 | Jun 17 |
| Walker Theodore C | President & CEO, PartnerRe NA | Feb 05 '15 | Option Exercise | 60.28 | 36,629 | 2,208,120 | 35,866 | Feb 09 |
| Walker Theodore C | President & CEO, PartnerRe NA | Feb 05 '15 | Sale | 121.06 | 2,874 | 347,933 | 32,992 | Feb 09 |
| Desmet Laurie | EVP & COO, PartnerRe Ltd | Feb 05 '15 | Option Exercise | 47.75 | 3,204 | 153,000 | 30,126 | Feb 06 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.